Navigation Links
Regulus Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
Date:5/14/2013

ing statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 Regulus Therapeutics Inc.Selected Financial InformationCondensed Statement of Operations(In thousands, except share and per share data)Three months endedMarch 31,20132012(Unaudited)Revenues:Revenues under strategic alliances and collaborations$ 3,238$ 3,344Operating expenses:Research and development6,8834,603General and administrative1,905921Total operating expenses8,7885,524Loss from operations(5,550)(2,180)Other income (expense), net(1,689)(66)Loss before income taxes(7,239)(2,246)Income tax (benefit) expense(10)1Net loss$

(7,229)$

(2,247)Basic and diluted net loss per share$

(0.20)$

(13.06)Shares used to compute basic and diluted net loss per share35,872,606171,998 

 Regulus Therapeutics Inc.Condensed Balance Sheets(In thousands)March 31,2013December 31,2012(Unaudited)AssetsCash, cash equivalents and short-term investments$

90,715$

98,100Other current assets1,054829Noncurrent assets5,2584,589Total assets$

97,027$<
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
2. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
3. Regulus to Present at Future Leaders in the Biotech Industry Conference
4. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
5. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
6. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
7. Regulus to Present at Two Upcoming Investor Conferences
8. Regulus Appoints Mark G. Foletta to its Board of Directors
9. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
10. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
11. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
(Date:7/24/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... fiscal year 2014 financial results after the market close ... will follow on the same day at 4:30 p.m. ... hosted by Dan Myers , President and Chief ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2Alimera Sciences To Release Second Quarter 2014 Results 2
... in LDL-C when Treated with 300 mg/week ISIS 301012 ... for 13 Weeks, - Study Presented in Poster Session Today at DALM Symposium in New York ... City, - Isis Will Host a Conference ... at http://www.isispharm.com , ...
... today,announced that the company has been awarded a ... and Technology (NIST) to develop a Sensor,System on ... markers in,a single assay. Successful development of ... of multifactorial conditions such as autoimmune disease and,allergy, ...
Cached Medicine Technology:Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 6Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 2Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 3Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 4
(Date:7/24/2014)... overweight and obese preschoolers works better when treatment targets ... child is targeted, according to research published this week ... at Buffalo and Women and Children,s Hospital of Buffalo., ... and had one parent who participated in the study ... mass index (BMI) measurements, calculated based on height and ...
(Date:7/24/2014)... 24, 2014 News Facts , ... has achieved certification for compliance with Department of ... by the DoD Information Assurance Certification and Accreditation ... identified within the DoD as the Enterprise Clinical ... designation from the U.S. Army Medical Materiel Agency. ...
(Date:7/24/2014)... material like a medical device or surgical implant is ... According to Northwestern University,s Guillermo Ameer, most of the ... device,s function. , "You will always get an inflammatory ... engineering in Northwestern,s McCormick School of Engineering and Applied ... of Medicine. "A problem with commonly used plastic materials, ...
(Date:7/24/2014)... 2014 A new study led by the Translational ... among bacteria, viruses and the immune system during HIV ... their potential to infect others based on their ... of virus in their semen despite having low levels ... levels of the virus can be found in different ...
(Date:7/24/2014)... 24, 2014 Horizon BCBSNJ’s second annual ... lucky family a rent-free week in a beautiful Lavallette ... 2014. Don’t miss your chance to win a week’s ... to all New Jersey residents, 25 or older.* Residents ... http://www.facebook.com/HorizonBCBSNJ . , “A family vacation at ...
Breaking Medicine News(10 mins):Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:Antioxidant biomaterial promotes healing 2Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2
... plague is significantly slowed when it can't make use of ... in St. Louis report in this week's issue of Science. ... plague, which kills in three to four days and potentially ... causes plague, Yersinia pestis, is vulnerable to antibiotics, but by ...
... dehydrogenase (ADH) is one of the major enzymes involved ... at two loci, ADH1B and ADH1C.// ,The ... linked with protection from alcohol dependence, a new study ... ADH1B*3 allele and alcohol-related disorders among Afro-Trinidadians. Findings indicate ...
... inflammatory disorder that causes degeneration of the nerves in ... including muscle// weakness and pain. ,Most ... remission, leading to the suggestion that there are regulatory ... model of MS (known as EAE), researchers from the ...
... Corps is to get a mega centre with multi-specialities, ... for this here Thursday.// ,The facility will ... (Research & Referral) and will be known as Army ... under one roof facilities for training dental officers, specialists ...
... (Zyban) and nortriptyline double a person’s chances //of giving ... reuptake inhibitors (SSRIs) such as fluoxetine (Prozac) are not ... to help people quit smoking, not everyone is helped ... alternative is to use antidepressants. The rationale for this ...
... India - Dr. Avul Pakir Jainulabdeen Abdul Kalam released ... Shri - on the eve of the Republic Day. ... Committee’ makes the final recommendations on awardees after receiving ... central ministries and departments and institutions of excellence, and ...
Cached Medicine News:Health News:Disabling Key Protein may Give Physicians Time to Treat Pneumonic Plague 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 3Health News:Majority of Padma Awards Go to Doctors from Delhi 2
Colloidal Gold Conjugated, Protein A - 50 OD...
Colloidal Gold Conjugated, Protein G - 50 OD...
Polyester ribbon impregnated with conjugated Protein G - .25 OD per sq. cm....
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: